ImmunityBio (IBRX) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 290.0% versus a gain of 11.8%. Over five years, MDGL leads with a +466.0% price change compared with +4.8% for IBRX. Madrigal Pharmaceuticals is the larger company by market cap ($11.02 billion vs $10.50 billion), about 1.0 times the size, while ImmunityBio is growing revenue faster (+668.3% vs +432.1%).
Madrigal Pharmaceuticals converts more of its revenue into profit, with a net margin of -30.1% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | MDGL |
|---|---|---|
| Share price | $9.91 | $476.91 |
| Market cap | $10.50B | $11.02B |
| 1-day change | +1.64% | -2.22% |
| YTD return | +392.42% | -16.25% |
| 1-year return | +290.00% | +11.79% |
| 5-year return | +4.84% | +466.00% |
| Forward P/E | — | 49.55 |
| EPS (TTM) | $-0.96 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $958.40M |
| Revenue growth (YoY) | +668.31% | +432.05% |
| Net income (latest FY) | $-351.40M | $-288.28M |
| Gross margin | 99.34% | — |
| Operating margin | -226.00% | -31.31% |
| Net margin | -310.18% | -30.08% |
| 52-week high | $12.43 | $615.00 |
| 52-week low | $1.95 | $393.61 |
| Distance from 52-week high | -20.27% | -22.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +28.66% | +43.03% |
| Average volume | 10.29M | 289.31K |
| Shares outstanding | 1.06B | 23.10M |
| Employees | 684 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed MDGL by 278.2 percentage points over the past year.
- Madrigal Pharmaceuticals is more profitable, keeping -30.1 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +432.05%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
IBRX vs MDGL FAQ
Which is bigger, ImmunityBio or Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $11.02B compared with $10.50B for ImmunityBio (IBRX).
Which stock has performed better over the past year, IBRX or MDGL?
IBRX returned +290.00% over the past 12 months, compared with +11.79% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Madrigal Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ImmunityBio and Biotechnology: Pharmaceutical Preparations for Madrigal Pharmaceuticals.